Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance

By sjmartinez • November 9, 2023

Karpouzas GA, Szekanecz Z, Baecklund E, Mikuls TR, Bhatt DL, Wang C, Sawyerr GA, Chen Y, Menon S, Connell CA, Ytterberg SR, Mortezavi M. Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance. Ther Adv Musculoskelet Dis. 2023 Nov 6;15:1759720X231201047. doi: 10.1177/1759720X231201047. PMID: 37942277; PMCID: PMC10629315.

Tags: autoinflammatory conditions, DMARDs, Inflammation, outcome measures, Publications, Rheumatoid arthritis, Rheumatology

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome After SARS-CoV-2 Infection

Unger ER, Lin JS, Wisk LE, Yu H, L'Hommedieu M, Lavretsky H, Montoy JCC, Gottlieb MA, Rising KL, Gentile NL, Santangelo M, Venkatesh AK, Rodriguez[...]

Features of HIV Infection in the Context of Long-Acting Cabotegravir Preexposure Prophylaxis

Landovitz RJ, Delany-Moretlwe S, Fogel JM, Eshleman SH, Marzinke MA, Piwowar-Manning E, Richardson P, Halvas EK, Mellors JW, Persaud D, Kofron R, McCauley M, Rose[...]

Association of Medication Adherence and Health Status in Heart Failure With Reduced Ejection Fraction: Insights From the CHAMP-HF Registry

El-Zein RS, Mohammed M, Nguyen DD, Hill CL Jr, Thomas L, Nassif M, DeVore AD, Albert NM, Butler J, Patterson JH, Williams FB, Hernandez A,[...]